PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
20.86%
Revenue growth above 1.5x CRON.TO's 3.70%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
30.04%
Gross profit growth above 1.5x CRON.TO's 5.61%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-72.06%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-130.61%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-61.23%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
100.00%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
100.00%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-100.00%
Share reduction while CRON.TO is at 25.88%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-100.00%
Reduced diluted shares while CRON.TO is at 25.88%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-122.31%
Negative OCF growth while CRON.TO is at 234.45%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-232.20%
Negative FCF growth while CRON.TO is at 94.16%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-100.00%
Negative 10Y revenue/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-100.00%
Negative 5Y CAGR while CRON.TO stands at 204.60%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-100.00%
Negative 3Y CAGR while CRON.TO stands at 41.58%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
100.00%
10Y OCF/share CAGR at 50-75% of CRON.TO's 199.63%. Martin Whitman might fear a structural deficiency in operational efficiency.
100.00%
5Y OCF/share CAGR is similar to CRON.TO's 106.62%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
100.00%
3Y OCF/share CAGR at 75-90% of CRON.TO's 115.92%. Bill Ackman would press for improvements in margin or overhead to catch up.
100.00%
Positive 10Y CAGR while CRON.TO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
100.00%
5Y net income/share CAGR above 1.5x CRON.TO's 66.60%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
100.00%
Positive short-term CAGR while CRON.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
-100.00%
Negative equity/share CAGR over 10 years while CRON.TO stands at 1410.50%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-100.00%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-100.00%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.53%
AR growth well above CRON.TO's 23.99%. Michael Burry fears inflated revenue or higher default risk in the near future.
2.84%
Inventory shrinking or stable vs. CRON.TO's 21.79%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-39.05%
Negative asset growth while CRON.TO invests at 1.85%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-100.00%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.41%
We’re deleveraging while CRON.TO stands at 10.68%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-60.00%
Our R&D shrinks while CRON.TO invests at 17.15%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
12.05%
SG&A growth well above CRON.TO's 8.16%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.